Pyxis Oncology (NASDAQ:PYXS) Receives Outperform Rating from Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report sent to investors on Friday,Benzinga reports. They currently have a $8.00 price objective on the stock, down from their previous price objective of $10.00.

PYXS has been the topic of a number of other reports. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Stephens assumed coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, November 21st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pyxis Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $9.43.

Pyxis Oncology Stock Up 9.7 %

Shares of PYXS stock opened at $1.69 on Friday. Pyxis Oncology has a 12-month low of $1.49 and a 12-month high of $6.85. The company has a market capitalization of $100.50 million, a PE ratio of -1.64 and a beta of 1.00. The firm has a 50 day moving average price of $2.93 and a two-hundred day moving average price of $3.30.

Insider Buying and Selling

In other news, CFO Pamela Ann Connealy acquired 88,850 shares of the stock in a transaction on Tuesday, November 26th. The stock was acquired at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the transaction, the chief financial officer now directly owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 9.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently modified their holdings of PYXS. MetLife Investment Management LLC boosted its stake in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after buying an additional 5,484 shares in the last quarter. Pier 88 Investment Partners LLC lifted its holdings in shares of Pyxis Oncology by 7.0% in the third quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock worth $446,000 after acquiring an additional 7,910 shares during the last quarter. Fullcircle Wealth LLC acquired a new stake in shares of Pyxis Oncology in the 2nd quarter valued at approximately $40,000. Jane Street Group LLC increased its position in Pyxis Oncology by 40.8% during the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after purchasing an additional 14,349 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in Pyxis Oncology in the 3rd quarter valued at approximately $55,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.